Next Article in Journal
Neuroinflammatory Loop in Schizophrenia, Is There a Relationship with Symptoms or Cognition Decline?
Previous Article in Journal
RiboTag RNA Sequencing Identifies Local Translation of HSP70 in Astrocyte Endfeet After Cerebral Ischemia
Previous Article in Special Issue
Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Macrophage Polarization: Learning to Manage It 3.0

Consiglio Nazionale delle Ricerche, Istituto per la Ricerca e l’Innovazione Biomedica, Via Ugo La Malfa 153, 90146 Palermo, Italy
Int. J. Mol. Sci. 2025, 26(1), 311; https://doi.org/10.3390/ijms26010311
Submission received: 28 November 2024 / Accepted: 29 December 2024 / Published: 1 January 2025
(This article belongs to the Special Issue Macrophage Polarization: Learning to Manage It 3.0)
Macrophages are cells of the innate immune system with very peculiar characteristics, so plastic that they respond rapidly to environmental changes by assuming different and sometimes contrasting functions, such as initiating a physiological inflammatory response or interrupting it and repairing damaged tissues. The definition of pro- and anti-inflammatory macrophages (classical M1 and alternative M2) is now outdated. Instead, we observe a continuum of different cell types between the two extremes (M1 and M2) that show some overlapping characteristics (e.g., production of the same cytokines) and others that are completely unique (e.g., production of pro- or anti-inflammatory cytokines and expression of receptors and CD markers). Therefore, macrophages may participate in the same event but with different functions [1,2]. This variety of cell types also includes tumor-associated macrophages (TAMs). TAMs can derive from either resident macrophages or from blood monocyte-derived macrophages (BMDMs) that migrate because they are attracted by factors produced by the tumor itself [3,4]. TAMs are known to promote tumorigenesis and cancer progression, in addition to inducing metastasis formation and resistance to chemotherapy and radiotherapy [5,6]. They constitute approximately 50% of the tumor mass and influence tumor cells (TCs), the tumor microenvironment (TEM), and cancer-associated fibroblasts (CAFs) [7]. TAMs showing the characteristics of the M2d macrophage subtype have been identified in the ascites of patients with ovarian cancer [7]. The repolarization or reprogramming strategy of TAMs is based on the well-known plasticity of macrophages and, therefore, on the possibility of redirecting the M2-like phenotype towards the M1-like phenotype, which can produce pro-inflammatory cytokines and chemokines directed against cancer [8]. To educate TAMs in a pro-inflammatory direction, it is necessary to manipulate the molecular nodes that distinguish the two main macrophage subtypes (M1 and M2). An interesting manuscript in this Special Issue addresses the role of PARylation in the polarization of TAMs [9]. The authors investigate poly(ADP-ribose) polymerase (PARP) enzymes, in particular, PARP14, which plays a role in breast cancer-induced TAM polarization. The results indicate the involvement of lipocalin-2 (LCN2), macrophage migration inhibitory factor (MIF), and plasminogen activator inhibitor-1 (PAI-1) in TAM polarization and suggest PARP14 as a possible target for TAM repolarization [9] (Figure 1).
To better understand the interactions between TAMs, tumor cells, and TME cues, 3D cell culture models have been developed (for a review, see [10]). Spheroids are a very simple 3D cell culture model for the study of cell–environment interactions. An interesting study explored the reprogramming of BMDMs under 3D free-floating conditions in the presence of breast cancer spheroids [11]. Tumor cell spheroids stimulated the production of immunosuppressive M2 markers, as well as pro-tumor cytokines and chemokines. Despite this, the reprogramming of BMDMs produced a mixed macrophage phenotype that expressed both immunosuppressive and immunostimulatory anti-tumor characteristics [11] (Figure 2).
The third study that addresses the repolarization of TAMs concerns a very particular target: V-set immunoglobulin domain-containing 4 (VSIG4) [12], a protein expressed exclusively by macrophages. In the TME, it is specifically expressed by TAMs [13] and is associated with a poor prognosis [14,15,16] (Figure 3).
The authors demonstrate that VSIG4 contributes to promoting the M2-like polarization of TAMs and therefore appears as a target for their reprogramming [12]. Furthermore, VSIG4 blockade also works as a monotherapy, since it can act in combination with the anti-PD-1 target [12]. PD-1 is an immune checkpoint considered a possible molecular target for TAM reprogramming, together with LncRNAs and miRNAs, signaling pathways, receptors, extracellular matrix components, and cytokines/chemokines [17] (Figure 4). The block of immune checkpoints and molecular targets are used to enhance the efficacy of conventional cancer therapies (chemotherapies/radiotherapies). Moreover, the inhibition of strategic pathways for TAM repolarization, such as NF-κB, can also lead to the downregulation of PD-1 checkpoint expression [18].
This Special Issue 3.0 focuses on the involvement of macrophage dysfunction and inflammation in the development of some diseases, their progression, or their worsening. Indeed, there are many pathologies with implications directly or indirectly related to macrophage polarization, ranging from autoimmune diseases to cancer, including all diseases that have chronic inflammation as their substrate [19,20,21,22]. A review in this Special Issue focuses on bioactive phospholipids such as lysophosphatidic acid (LPA) and their physiological and pathological functions, including cell migration, apoptosis, and proliferation [23].
Indeed, LPA is present in human bronchoalveolar lavage fluid (BALF) and increases after allergic inflammation [24]. Allergic asthma is often characterized by chronic airway inflammation, and asthma therapy targets LPA receptor 2 (LPA2). The LPA-producing enzyme autotaxin (ATX) is predominantly expressed in alveolar macrophages and bronchial epithelial cells and converts lysophospholipids (LPLs) to LPA [25]. The ATX/LPA signaling pathway is active in lung fibrosis via LPA receptor 1 (LPA1). It exacerbates chronic inflammation in chronic disease situations by generating cytokines and attracting inflammatory cells into the local tissue environment [26]. In fact, inhibition of the LPA1 receptor is a strategy used in preclinical studies and clinical trials to reduce pathologies that induce pulmonary fibrosis (PF) [27]. The macrophage is the most active cell type in lipid metabolism, and in PF, most of the lipid metabolism genes are altered [28]. In Chronic Obstructive Pulmonary Disease (COPD), there is an increased number of macrophages with phenotypic and functional changes related to their plasticity [29]. The molecular changes underlying PF and pulmonary emphysema (PE) found in COPD patients—including genetic and epigenetic changes—have been elucidated in a recent review [30]. In this Special Issue, a review explored macrophage polarization and function in COPD patients [31].
Functional changes include impaired phagocytosis and high lipid load in macrophages [32]. Inhibition of sphingosine 1-phosphate (S1P) signaling pathways suppresses the phagocytic capacity of alveolar macrophages (AMSs) [33]. A decreased phagocytic capacity is associated with an increased likelihood of pulmonary bacterial colonization by Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis [34,35] and viral colonization in the lungs of COPD patients. As a consequence of the dysfunction of these macrophages, their number increases significantly, but bacterial colonization of the lower airways in COPD patients increases the frequency of exacerbations and the progression of the disease [36,37]. The World Health Organization (WHO) recently published a Tobacco Knowledge Summary (TKS) that highlights that smoking is the main cause of COPD (about 70%) in most developed countries [38]. COPD patients also have a significantly higher risk of developing lung cancer, cardiovascular disease, and type II diabetes [38]. Nicotine is the main psychoactive component of tobacco. Nicotine transiently activates and deactivates monocyte–macrophages, reducing their ability to fight bacterial and viral infections through the induction of interleukin-1 receptor associated kinase-M (IRAK-M) expression, NF-kB-inhibition, and NLRP3-dependent IL-1β production [39]. Macrophages express nicotinic acetylcholine receptors (nAChRs) [40]. The induction of IRAK-M by nicotine is mediated by the 7-nAChR receptor [39]. The 7-nAChR receptor is involved in the activation of the cholinergic anti-inflammatory pathway, helping to mitigate excessive inflammation and maintain host homeostasis [41]. A review in this Special Issue details the cholinergic constituents present in macrophagesin particular, the 7-nAChR signaling pathway—and discusses their role in promoting macrophage polarization toward anti-inflammatory phenotypes [42]. Furthermore, the consequences of viral infections on macrophage inflammatory phenotypes are explored, taking cholinergic mechanisms into account.
Overall, this Special Issue 3.0 provides a collection of reviews and original articles covering different aspects of macrophage polarization, from macrophage reprogramming as a strategy to fight cancer to microenvironment-induced polarization to mitigate inflammation, which is a substrate of some diseases. The various articles thoroughly illustrate the latest progress in understanding some mechanisms underlying macrophage plasticity.

Funding

This research received no external funding.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Ross, E.A.; Devitt, A.; Johnson, J.R. Macrophages: The good, the bad, and the gluttony. Front. Immunol. 2021, 12, 708186. [Google Scholar] [CrossRef] [PubMed]
  2. Nasir, I.; McGuinness, C.; Poh, A.R.; Ernst, M.; Darcy, P.K.; Britt, K.L. Tumor Macrophage Functional Heterogeneity Can Inform the Development of Novel Cancer Therapies. Trends Immunol. 2023, 44, 971–985. [Google Scholar] [CrossRef] [PubMed]
  3. Tcyganov, E.; Mastio, J.; Chen, E.; Gabrilovich, D.I. Plasticity of Myeloid-Derived Suppressor Cells in Cancer. Curr. Opin. Immunol. 2018, 51, 76–82. [Google Scholar] [CrossRef]
  4. Kwak, T.; Wang, F.; Deng, H.; Condamine, T.; Kumar, V.; Perego, M.; Kossenkov, A.; Montaner, L.J.; Xu, X.; Xu, W.; et al. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Rep. 2020, 33, 108571. [Google Scholar] [CrossRef] [PubMed]
  5. Lin, Y.; Xu, J.; Lan, H. Tumor-Associated Macrophages in Tumor Metastasis: Biological Roles and Clinical Therapeutic Applications. J. Hematol. Oncol. 2019, 12, 76. [Google Scholar] [CrossRef] [PubMed]
  6. Pittet, M.J.; Michielin, O.; Migliorini, D. Clinical Relevance of Tumor-Associated Macrophages. Nat. Rev. Clin. Oncol. 2022, 19, 402–421. [Google Scholar] [CrossRef]
  7. Duluc, D.; Delneste, Y.; Tan, F.; Moles, M.-P.; Grimaud, L.; Lenoir, J.; Preisser, L.; Anegon, I.; Catala, L.; Ifrah, N.; et al. Tumor associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110, 4319–4330. [Google Scholar] [CrossRef] [PubMed]
  8. Liu, C.; Wang, Y.; Li, L.; He, D.; Chi, J.; Li, Q.; Wu, Y.; Zhao, Y.; Zhang, S.; Wang, L.; et al. Engineered Extracellular Vesicles and Their Mimetics for Cancer Immunotherapy. J. Control. Release 2022, 349, 679–698. [Google Scholar] [CrossRef] [PubMed]
  9. Sturniolo, I.; Váróczy, C.; Regdon, Z.; Mázló, A.; Muzsai, S.; Bácsi, A.; Intili, G.; Hegedus, C.; Boothby, M.R.; Holechek, J.; et al. PARP14 Contributes to the Development of the Tumor-Associated Macrophage Phenotype. Int. J. Mol. Sci. 2024, 25, 3601. [Google Scholar] [CrossRef] [PubMed]
  10. Cutter, S.; Wright, M.D.; Reynolds, N.P.; Binge, K.J. Towards using 3D cellular cultures to model the activation and diverse functions of macrophages. Biochem. Soc. Trans. 2023, 51, 387–401. [Google Scholar] [CrossRef]
  11. Korotkaja, K.; Jansons, J.; Spunde, K.; Rudevica, Z.; Zajakina, A. Establishment and Characterization of Free-Floating 3D Macrophage Programming Model in the Presence of Cancer Cell Spheroids. Int. J. Mol. Sci. 2023, 24, 10763. [Google Scholar] [CrossRef]
  12. Sazinsky, S.; Zafari, M.; Klebanov, B.; Ritter, J.; Nguyen, P.A.; Phennicie, R.T.; Wahle, J.; Kauffman, K.J.; Razlog, M.; Manfra, D.; et al. Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types. Int. J. Mol. Sci. 2024, 25, 6160. [Google Scholar] [CrossRef]
  13. Jung, K.; Jeon, Y.K.; Jeong, D.H.; Byun, J.M.; Bogen, B.; Choi, I. VSIG4-expressing tumor-associated macrophages impair anti-tumor immunity. Biochem. Biophys. Res. Commun. 2022, 628, 18–24. [Google Scholar] [CrossRef] [PubMed]
  14. Liao, Y.; Guo, S.; Chen, Y.; Cao, D.; Xu, H.; Yang, C.; Fei, L.; Ni, B.; Ruan, Z. VSIG4 expression on macrophages facilitates lung cancer development. Lab. Investig. 2014, 94, 706–715. [Google Scholar] [CrossRef] [PubMed]
  15. Roh, J.; Jeon, Y.; Lee, A.-N.; Lee, S.M.; Kim, Y.; Sung, C.O.; Park, C.-J.; Hong, J.Y.; Yoon, D.H.; Suh, C.; et al. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget 2017, 8, 58122–58132. [Google Scholar] [CrossRef] [PubMed]
  16. Xu, T.; Jiang, Y.; Yan, Y.; Wang, H.; Lu, C.; Xu, H.; Li, W.; Fu, D.; Lu, Y.; Chen, J. VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients. Am. J. Transl. Res. 2015, 7, 1172–1180. [Google Scholar] [PubMed]
  17. Lampiasi, N. New Strategies for Macrophage Re-Education in Cancer: An Update. Int. J. Mol. Sci. 2024, 25, 3414. [Google Scholar] [CrossRef] [PubMed]
  18. Liu, Y.; Liang, S.; Jiang, D.; Gao, T.; Fang, Y.; Fu, S.; Guan, L.; Zhang, Z.; Mu, W.; Chu, Q.; et al. Manipulation of TAMs functions to facilitate the immune therapy effects of immune checkpoint antibodies. J. Control. Release 2021, 336, 621–634. [Google Scholar] [CrossRef] [PubMed]
  19. Li, Z.; Liu, H.; Xie, Q.; Yin, G. Macrophage involvement in idiopathic inflammatory myopathy: Pathogenic mechanisms and therapeutic prospects. J. Inflamm. 2024, 21, 48. [Google Scholar] [CrossRef] [PubMed]
  20. Yang, X.; Li, J.; Xu, C.; Zhang, G.; Che, X.; Yang, J. Potential mechanisms of rheumatoid arthritis therapy: Focus on macrophage. polarization. Int. Immunopharmacol. 2024, 142 Pt A, 113058. [Google Scholar] [CrossRef]
  21. Ma, Y.; Sun, Y.; Guo, H.; Yang, R. Tumor-associated macrophages in bladder cancer: Roles and targeted therapeutic strategies. Int. Immunopharmacol. 2024, 15, 1418131. [Google Scholar] [CrossRef] [PubMed]
  22. Sedighzadeh, S.S.; Khoshbin, A.P.; Razi, S.; Keshavarz-Fathi, M.; Rezaei, N. A narrative review of tumor-associated macrophages in lung cancer: Regulation of macrophage polarization and therapeutic implications. Transl. Lung Cancer Res. 2021, 10, 1889–1916. [Google Scholar] [CrossRef]
  23. Jiang, S.; Yang, M.; Li, M. Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases. Int. J. Mol. Sci. 2023, 24, 12524. [Google Scholar] [CrossRef] [PubMed]
  24. Georas, S.N.; Berdyshev, E.; Hubbard, W.; Gorshkova, I.A.; Usatyuk, P.V.; Saatian, B.; Myers, A.C.; Williams, M.A.; Xiao, H.Q.; Liu, M.; et al. Lysophosphatidic acid is detectable in human bronchoalveolar fluids at baseline and increased after segmental allergen challenge. Clin. Exp. Allergy 2007, 37, 311–322. [Google Scholar] [CrossRef] [PubMed]
  25. Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781, 513–518. [Google Scholar] [CrossRef] [PubMed]
  26. Benesch, M.G.K.; MacIntyre, I.T.K.; McMullen, T.P.W.; Brindley, D.N. Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation. Cancers 2018, 10, 73. [Google Scholar] [CrossRef] [PubMed]
  27. Shi, X.; Chen, Y.; Shi, M.; Gao, F.; Huang, L.; Wang, W. The novel molecular mechanism of pulmonary fibrosis: Insight into lipid metabolism from reanalysis of single-cell RNA-seq databases. Lipids Health Dis. 2024, 23, 98. [Google Scholar] [CrossRef] [PubMed]
  28. Volkmann, E.R.; Denton, C.P.; Kolb, M.; Wijsenbeek-Lourens, M.S.; Emson, C.; Hudson, K.; Amatucci, A.J.; Distler, O.; Allanore, Y.; Khanna, D. Lysophosphatidic acid receptor 1 inhibition: A potential treatment target for pulmonary fibrosis. Eur. Respir. Rev. 2024, 33, 240015. [Google Scholar] [CrossRef] [PubMed]
  29. Barnes, P.J. Alveolar macrophages as orchestrators of COPD. COPD J. Chronic Obstr. Pulm. Dis. 2004, 1, 59–70. [Google Scholar] [CrossRef] [PubMed]
  30. Baltazar-García, E.A.; Vargas-Guerrero, B.; Gasca-Lozano, L.E.; Gurrola-Díaz, C.M. Molecular changes underlying pulmonary emphysema and chronic bronchitis in Chronic Obstructive Pulmonary Disease: An updated review. Histol. Histopathol. 2024, 39, 805–816. [Google Scholar] [PubMed]
  31. Kim, G.D.; Lim, E.Y.; Shin, H.S. Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2024, 25, 5631. [Google Scholar] [CrossRef] [PubMed]
  32. Weigert, A.; Olesch, C.; Brüne, B. Sphingosine-1-Phosphate and Macrophage Biology-How the Sphinx Tames the Big Eater. Front. Immunol. 2019, 10, 1706. [Google Scholar] [CrossRef]
  33. Tran, H.B.; Jersmann, H.; Truong, T.T.; Hamon, R.; Roscioli, E.; Ween, M.; Pitman, M.R.; Pitson, S.M.; Hodge, G.; Reynolds, P.N.; et al. Disrupted epithelial/macrophage crosstalk via Spinster homologue 2-mediated S1P signaling may drive defective macrophage phagocytic function in COPD. PLoS ONE 2017, 12, e0179577. [Google Scholar] [CrossRef] [PubMed]
  34. Walton, E.L. Microbes are off the menu: Defective macrophage phagocytosis in COPD. Biomed. J. 2017, 40, 301–304. [Google Scholar] [CrossRef]
  35. Papi, A.; Bellettato, C.M.; Braccioni, F.; Romagnoli, M.; Casolari, P.; Caramori, G.; Fabbri, L.M.; Johnston, S.L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006, 173, 1114–1121. [Google Scholar] [CrossRef] [PubMed]
  36. Patel, I.S.; Seemungal, T.A.; Wilks, M.; Lloyd-Owen, S.J.; Donaldson, G.C.; Wedzicha, J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57, 759–764. [Google Scholar] [CrossRef] [PubMed]
  37. Singh, R.; Belchamber, K.B.R.; Fenwick, P.S.; Chana, K.; Donaldson, G.; Wedzicha, J.A.; Barnes, P.J.; Donnelly, L.E.; COPDMAP Consortium. Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD. Respir. Res. 2021, 22, 113. [Google Scholar] [CrossRef] [PubMed]
  38. Lu, W.; Aarsand, R.; Schotte, K.; Han, J.; Lebedeva, E.; Tsoy, E.; Maglakelidze, N.; Soriano, J.B.; Bill, W.; Halpin, D.M.G. Tobacco and COPD: Presenting the World Health Organization (WHO) Tobacco Knowledge Summary. Respir. Res. 2024, 25, 338. [Google Scholar] [CrossRef] [PubMed]
  39. Zhan, L.; Luo, S.; Wang, H.; Wang, J.; Pan, X.; Lin, Y.; Jin, B.; Liang, Y.; Peng, C. Nicotine-induced transient activation of monocytes facilitates immunosuppressive macrophage polarization that restrains T Helper 17 cell expansion. Inflammation 2024. [Google Scholar] [CrossRef]
  40. Wang, H.; Yu, M.; Ochani, M.; Amella, C.A.; Tanovic, M.; Susarla, S.; Li, J.H.; Wang, H.; Yang, H.; Ulloa, L.; et al. Nicotinic Acetylcholine Receptor Alpha7 Subunit Is an Essential Regulator of Inflammation. Nature 2003, 421, 384–388. [Google Scholar] [CrossRef] [PubMed]
  41. Wu, X.J.; Yan, X.T.; Yang, X.M.; Zhang, Y.; Wang, H.Y.; Luo, H.; Fang, Q.; Li, H.; Li, X.Y.; Chen, K.; et al. GTS-21 ameliorates polymicrobial sepsis-induced hepatic injury by modulating autophagy through α7nAchRs in mice. Cytokine 2020, 128, 155019. [Google Scholar] [CrossRef]
  42. Roa-Vidal, N.; Rodríguez-Aponte, A.S.; Lasalde-Dominicci, J.A.; Capó-Vélez, C.M.; Delgado-Vélez, M. Cholinergic Polarization of Human Macrophages. Int. J. Mol. Sci. 2023, 24, 15732. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Schematic representation of the rationale behind PARP14 inhibition to achieve a switch from anti-inflammatory to pro-inflammatory macrophages. Down arrows indicate decreased expression.
Figure 1. Schematic representation of the rationale behind PARP14 inhibition to achieve a switch from anti-inflammatory to pro-inflammatory macrophages. Down arrows indicate decreased expression.
Ijms 26 00311 g001
Figure 2. Schematic representation of programming and reprogramming macrophage phenotypes strategy.
Figure 2. Schematic representation of programming and reprogramming macrophage phenotypes strategy.
Ijms 26 00311 g002
Figure 3. VSIG4 expression is restricted to tumor-associated myeloid populations. (A) Monoclonal antibody VSIG4 (mAb-VSIG4) leads to the repolarization of TAMs to an inflammatory M1-like phenotype. (B) VSIG4 acts as an inhibitory molecule that suppresses the cells that express it and inhibits T-cell proliferation and cytokine production, promoting tumor growth.
Figure 3. VSIG4 expression is restricted to tumor-associated myeloid populations. (A) Monoclonal antibody VSIG4 (mAb-VSIG4) leads to the repolarization of TAMs to an inflammatory M1-like phenotype. (B) VSIG4 acts as an inhibitory molecule that suppresses the cells that express it and inhibits T-cell proliferation and cytokine production, promoting tumor growth.
Ijms 26 00311 g003
Figure 4. Expression and function of immune checkpoints PD-L1 and PD-1 in macrophages and tumor cells (TCs). (A) TAMs can indirectly inhibit immune activation by enhancing PD-L1 expression on TCs through the release of exosomes and anti-inflammatory cytokines. PD-L1 expressed on TCs binds to PD-1 expressed on T cells and inhibits the cytotoxic effects of T cells. (B) TAMs can directly inhibit immune activation because they increase their expression of PD-L1 due to the phagocytosis of PD-L1-carrying exosomes produced by TCs. (C) M1 macrophages can directly inhibit tumor growth by inhibiting PD-L1 expression in TCs through the release of exosomes carrying miR16-5p. (D) PD-1-expressing TAMs inhibit macrophage phagocytosis and promote tumor growth and metastasis. Adopted from [17].
Figure 4. Expression and function of immune checkpoints PD-L1 and PD-1 in macrophages and tumor cells (TCs). (A) TAMs can indirectly inhibit immune activation by enhancing PD-L1 expression on TCs through the release of exosomes and anti-inflammatory cytokines. PD-L1 expressed on TCs binds to PD-1 expressed on T cells and inhibits the cytotoxic effects of T cells. (B) TAMs can directly inhibit immune activation because they increase their expression of PD-L1 due to the phagocytosis of PD-L1-carrying exosomes produced by TCs. (C) M1 macrophages can directly inhibit tumor growth by inhibiting PD-L1 expression in TCs through the release of exosomes carrying miR16-5p. (D) PD-1-expressing TAMs inhibit macrophage phagocytosis and promote tumor growth and metastasis. Adopted from [17].
Ijms 26 00311 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lampiasi, N. Macrophage Polarization: Learning to Manage It 3.0. Int. J. Mol. Sci. 2025, 26, 311. https://doi.org/10.3390/ijms26010311

AMA Style

Lampiasi N. Macrophage Polarization: Learning to Manage It 3.0. International Journal of Molecular Sciences. 2025; 26(1):311. https://doi.org/10.3390/ijms26010311

Chicago/Turabian Style

Lampiasi, Nadia. 2025. "Macrophage Polarization: Learning to Manage It 3.0" International Journal of Molecular Sciences 26, no. 1: 311. https://doi.org/10.3390/ijms26010311

APA Style

Lampiasi, N. (2025). Macrophage Polarization: Learning to Manage It 3.0. International Journal of Molecular Sciences, 26(1), 311. https://doi.org/10.3390/ijms26010311

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop